Vectura Group PLC (VEC) Insider Buys £149.81 in Stock

Vectura Group PLC (LON:VEC) insider Andrew Derodra purchased 211 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The shares were purchased at an average cost of GBX 71 ($0.98) per share, with a total value of £149.81 ($206.98).

Andrew Derodra also recently made the following trade(s):

  • On Wednesday, January 17th, Andrew Derodra acquired 127 shares of Vectura Group stock. The shares were bought at an average price of GBX 118 ($1.63) per share, for a total transaction of £149.86 ($207.05).
  • On Friday, December 8th, Andrew Derodra acquired 153 shares of Vectura Group stock. The shares were bought at an average price of GBX 98 ($1.35) per share, for a total transaction of £149.94 ($207.16).

Shares of Vectura Group PLC (LON:VEC) opened at GBX 77.35 ($1.07) on Thursday. Vectura Group PLC has a fifty-two week low of GBX 70.50 ($0.97) and a fifty-two week high of GBX 166.97 ($2.31).

A number of equities research analysts have issued reports on the company. Shore Capital restated a “buy” rating on shares of Vectura Group in a research report on Thursday, November 9th. Peel Hunt restated a “hold” rating and set a GBX 160 ($2.21) price objective on shares of Vectura Group in a research report on Thursday, February 1st. Numis Securities restated a “buy” rating and set a GBX 170 ($2.35) price objective on shares of Vectura Group in a research report on Thursday, January 4th. Royal Bank of Canada upgraded Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price objective on the stock in a research report on Thursday, December 14th. Finally, JPMorgan Chase & Co. restated an “overweight” rating on shares of Vectura Group in a research report on Monday, January 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Vectura Group has an average rating of “Buy” and an average target price of GBX 169.56 ($2.34).

TRADEMARK VIOLATION WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/15/vectura-group-plc-vec-insider-buys-149-81-in-stock.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Insider Buying and Selling by Quarter for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply